ストックスクリーナーアプリを入手
20.45
0.05%
0.0002
前日終値:
$20.45
開ける：
$20.53
24時間の取引高:
698.77K
Relative Volume:
0.72
時価総額：
$12.99B
収益：
$2.75B
当期純損益:
$799.51M
株価収益率:
20.41
EPS:
1.0022
ネットキャッシュフロー:
$940.04M
1週間 パフォーマンス:
-3.40%
1か月 パフォーマンス:
-10.18%
6か月 パフォーマンス:
-29.81%
1年 パフォーマンス:
-34.00%
1日の値動き範囲:
$20.34
$20.62
1週間の範囲:
$20.34
$21.01
52週間の値動き範囲:
$20.34
$32.88
Genmab Adr Stock (GMAB) Company Profile
GMAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| GMAB | 20.46 | 12.99B | 2.75B | 799.51M | 940.04M | 1.0022 |
| VRTX | 447.88 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.88 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.97 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.82 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-23 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | ダウングレード | Citigroup | Neutral → Sell |
| 2023-12-06 | アップグレード | UBS | Neutral → Buy |
| 2023-11-10 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-11-08 | アップグレード | DNB Markets | Sell → Buy |
| 2023-10-18 | 開始されました | Exane BNP Paribas | Underperform |
| 2023-09-06 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | 開始されました | BTIG Research | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-31 | 開始されました | UBS | Neutral |
| 2023-05-12 | 開始されました | Morgan Stanley | Underweight |
| 2022-12-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-11-14 | 開始されました | William Blair | Mkt Perform |
| 2022-11-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2022-06-24 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-05-02 | 開始されました | Cowen | Market Perform |
| 2022-03-16 | アップグレード | UBS | Neutral → Buy |
| 2022-01-31 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-12-01 | 開始されました | Berenberg | Sell |
| 2021-09-16 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | 開始されました | Deutsche Bank | Buy |
| 2021-01-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | ダウングレード | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-06-25 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | 開始されました | Credit Suisse | Outperform |
| 2020-02-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-12-12 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-09-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-08-12 | 開始されました | Guggenheim | Buy |
| 2019-08-12 | 開始されました | Morgan Stanley | Overweight |
| 2019-08-12 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Genmab Adr (GMAB) 最新ニュース
10 Biggest Biotechnology Companies - Investopedia
Weekly Upgrades and Downgrades - InvestorPlace
Genmab to Present at Jefferies London Healthcare Conference - GlobeNewswire Inc.
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? - Yahoo Finance
Is Genmab (GMAB) Stock Undervalued Right Now? - Yahoo Finance
GMAB or INCY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround - Yahoo Finance
Market Resilience: Genmab ADR (GMAB) Finishes Weak at 24.14, Down -5.44 - The Dwinnex
GANDHIM.APPL Share Price Today Up 13% - Equitymaster
Glenmark Pharma Share Price Today Down 3% - Equitymaster
Post-Trade Analysis: Genmab ADR (GMAB) Climbs 1.55, Closing at 26.90 - The Dwinnex
Market Recap: Genmab ADR (GMAB)’s Negative Momentum, Closing at 27.41 - The Dwinnex
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy - MSN
Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet - Yahoo Finance
GMAB vs. CSLLY: Which Stock Is the Better Value Option? - Yahoo Finance
GMAB’s Stock Journey: What Investors Need to Know About Genmab ADR’s Performance - The InvestChronicle
Wall Street Analysts Believe Genmab (GMAB) Could Rally 52.33%: Here's is How to Trade - Zacks Investment Research
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024 - GlobeNewswire Inc.
ISS suggest Enhabit shareholders elect three AREX Capital nominees to board By Reuters - Investing.com
Antibody Drug Conjugates Market Insights 2018-2023 and - GlobeNewswire Inc.
AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock? - Zacks Investment Research
GMAB or TECH: Which Is the Better Value Stock Right Now? - Yahoo Finance
GMAB vs. TECH: Which Stock Is the Better Value Option? - Yahoo Finance
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now? - Yahoo Canada Shine On
Zacks.com featured highlights include Tap Genmab, KnowBe4, UserTesting, Enphase Energy and Gartner - Yahoo Lifestyle UK
Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag - Yahoo Sport Australia
Zacks.com featured highlights Genmab, Hologic, ServiceNow and Splunk - Yahoo New Zealand News
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue? - Yahoo New Zealand News
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma - Yahoo Finance
AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag - Yahoo New Zealand News
GILD or GMAB: Which Is the Better Value Stock Right Now? - Yahoo New Zealand News
Genmab A/S executes share buyback program - Investing.com India
Genmab advances share buy-back program - Investing.com India
Ratio Revelations: Genmab ADR (GMAB)'s Financial Metrics in the Spotlight – DWinneX - The Dwinnex
Truist Securities ups Genmab shares target By Investing.com - Investing.com
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier - Yahoo Lifestyle UK
Genmab ADR (GMAB)'s stock chart: A technical perspective – US Post News - US Post News
Genmab ADR (GMAB) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Genmab completes $1.8 billion acquisition of ProfoundBio By Investing.com - Investing.com
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run? - Yahoo Singapore News
Is Genmab (GMAB) Outperforming Other Medical Stocks This Year? - Yahoo Lifestyle UK
500: Something went wrong - Investing.com
Earnings call: Genmab reports strong Q1 growth, plans ProfoundBio acquisition - Investing.com
GMAB: 3 Biotech Stocks Gaining Altitude and Interest - StockNews.com
Genmab's 'Evolution' Continues With A $1.8 Billion Deal; But Shares Slip - Investor's Business Daily
GMAB: Bank on the Future Returns With These 3 Biotech Stocks - StockNews.com
New Strong Buy Stocks for January 17th - Yahoo Finance
Pfizer and Genmab's TIVDAK gains FDA priority review for cervical cancer - Investing.com South Africa
GMAB: 3 Biotech Stocks to Boost Portfolios - StockNews.com
Genmab Adr (GMAB) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):